⚕️ Education, not medical advice
This course surveys experimental and frontier longevity interventions for general understanding. NONE of it is medical advice or a recommendation to take any drug, compound, or therapy. Most interventions here are unproven in healthy humans and carry real risks — anything you'd consider belongs in the hands of a qualified clinician.
The most advanced frontier interventions are repurposed and experimental DRUGS — compounds with real mechanistic rationale and, in some cases, decades of human safety data for other uses. Here are the leading candidates, and an honest assessment of where each really stands.
Learning Objectives
- •Understand the leading longevity drug candidates
- •Learn the landmark human aging trials
- •Grasp the honest clinical status
Rapamycin: the front-runner
RAPAMYCIN (an mTOR inhibitor) is arguably the most robust longevity drug in animal studies — it reliably extends lifespan in mice, even when started late in life. In humans it's an approved drug (for transplants and other uses), so its safety profile is known: at high daily 'transplant' doses it suppresses immunity, but researchers are studying LOWER, INTERMITTENT doses for aging, where some trials have even shown IMPROVED immune responses in older adults. It's used off-label by some, but is NOT proven or approved for healthy-human longevity.
Metformin and the TAME trial
METFORMIN, a cheap, decades-old diabetes drug, is studied for aging because of its metabolic and AMPK-related effects and observational hints of broad benefit. Its importance is partly symbolic: the proposed TAME trial (Targeting Aging with Metformin) is designed to test whether a drug can delay MULTIPLE age-related diseases at once — which would be a landmark for the whole geroscience approach, by getting regulators to treat 'aging' as a target. The trial faces funding and design challenges and remains a work in progress.
Other repurposed candidates
Several other existing drugs show promise in animal studies (e.g. via the rigorous Interventions Testing Program): acarbose (which blunts glucose spikes), certain SGLT2 inhibitors, and others. The appeal of REPURPOSING approved drugs is that their safety is already established, lowering one hurdle. But efficacy for human AGING specifically remains unproven for all of them — animal lifespan extension is a starting point, not a human endorsement.
The honest clinical status
The bottom line across all of these: as of now, NO drug is proven or approved to extend healthy human lifespan. The mechanisms are real, the animal data are often strong, and the human trials are genuinely important — but the verdict isn't in. People using these off-label are running personal experiments, not following established medicine, and doing so carries real risks (rapamycin's immune effects, for instance). Promising science; unproven therapy.
Why a human longevity trial is so hard to run
Testing whether a drug extends human LIFESPAN directly is nearly impossible — it would take decades and enormous numbers of people. That's why trials like TAME instead measure whether an intervention delays the ONSET of multiple age-related DISEASES over a shorter window, using that as a proxy for slowed aging. The sheer difficulty of proving longevity benefit in humans is a core reason the field moves slowly and the frontier stays 'unproven' for so long.
Longevity drugs, by the numbers
- ▸Rapamycin (mTOR inhibitor) robustly extends mouse lifespan; studied at low intermittent doses in humans
- ▸Metformin's TAME trial aims to test whether a drug can delay multiple age-related diseases at once
- ▸Repurposing approved drugs leverages known safety but not proven aging efficacy
- ▸No drug is yet proven or approved to extend healthy human lifespan
Rapamycin and metformin are proven anti-aging drugs for healthy people.
Both have real mechanistic rationale and (for metformin) decades of safety data, but NEITHER is proven or approved to extend healthy human lifespan. The animal data and human trials are promising and important — but off-label use is personal experimentation with real risks, not established medicine.
Quick Check
Why is the TAME trial considered landmark for the longevity field?
Quick Check
What is the honest clinical status of longevity drugs like rapamycin and metformin?
True or False
Directly proving a drug extends human lifespan in a trial is extremely difficult.
Summary
- →Rapamycin (mTOR) is the most robust animal longevity drug; studied low/intermittent in humans
- →Metformin's TAME trial aims to validate targeting aging by delaying multiple diseases
- →Repurposed drugs (acarbose, etc.) leverage known safety but unproven aging efficacy
- →No drug is yet proven or approved for healthy-human longevity — off-label use is experimentation
One of the most exciting new drug classes targets the 'zombie' cells of aging. Next: senolytics.